Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.31
-0.26 (-1.57%)
Apr 23, 2026, 4:00 PM EDT - Market closed
Theravance Biopharma Employees
Theravance Biopharma had 90 employees as of December 31, 2025. The number of employees decreased by 7 or -7.22% compared to the previous year.
Employees
90
Change (1Y)
-7
Growth (1Y)
-7.22%
Revenue / Employee
$1,194,044
Profits / Employee
$1,176,611
Market Cap
839.85M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 90 | -7 | -7.22% | 90 | 0 |
| Dec 31, 2024 | 97 | -2 | -2.02% | 97 | 0 |
| Dec 31, 2023 | 99 | -12 | -10.81% | 99 | 0 |
| Dec 31, 2022 | 111 | -48 | -30.19% | 111 | 0 |
| Dec 31, 2021 | 159 | -200 | -55.71% | 158 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MannKind | 592 |
| Kura Oncology | 260 |
| ARS Pharmaceuticals | 163 |
| Solid Biosciences | 121 |
| Cullinan Therapeutics | 109 |
| Vor Biopharma | 76 |
| Design Therapeutics | 54 |
| Bright Minds Biosciences | 26 |
TBPH News
- 21 days ago - TBPH Investors Have Opportunity to Join Theravance Biopharma, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 5 weeks ago - Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 7 weeks ago - Theravance Biopharma Plummets As Phase 3 Study Falls Short - Benzinga
- 7 weeks ago - Theravance plans strategic review, including possible sale, after drug trial failure - Reuters
- 7 weeks ago - Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions - PRNewsWire
- 5 months ago - Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025 - PRNewsWire
- 5 months ago - Theravance Biopharma to Participate in Upcoming Investor Conferences - PRNewsWire
- 5 months ago - Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire